Urinary calcium oxalate crystal growth inhibitors.
暂无分享,去创建一个
[1] E. Worcester,et al. Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. , 1995, Kidney international.
[2] P. Jaeger,et al. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. , 1993, The American journal of physiology.
[3] R. Ryall,et al. Immunohistochemical distribution and quantification of crystal matrix protein. , 1993, Kidney international.
[4] P. Waterhouse,et al. Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[5] J. Lieske,et al. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. , 1993, The American journal of physiology.
[6] M. Daudon,et al. Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. , 1993, Biochemical and biophysical research communications.
[7] J. Davison,et al. Increases in Urinary Inhibitor Activity and Excretion of an Inhibitor of Crystalluria in Pregnancy: A Defense Against the Hypercalciuria of Normal Gestation , 1993 .
[8] F. Coe,et al. The pathogenesis and treatment of kidney stones. , 1992, The New England journal of medicine.
[9] E. Manseau,et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. , 1992, Molecular biology of the cell.
[10] E. Worcester,et al. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] E. Neilson,et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[12] F. Coe,et al. Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. , 1991, The American journal of physiology.
[13] P. Chang,et al. 1 alpha,25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. , 1991, Cancer research.
[14] F. Coe,et al. Inhibitors within the nephron. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] J. Parks,et al. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. , 1991, The American journal of physiology.
[16] A. Hesse,et al. Significance of glycosaminoglycans for the formation of calcium oxalate stones. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] Y. Nakagawa,et al. Isolation of nephrocalcin from kidney tissue of nine vertebrate species. , 1991, The American journal of physiology.
[18] H. DeLuca,et al. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[19] B. B. Mukherjee,et al. Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. , 1990, The Journal of biological chemistry.
[20] Qi Zhang,et al. Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. , 1989, Biochemical and biophysical research communications.
[21] F. Coe,et al. Elucidation of multiple forms of nephrocalcin by 31P‐NMR spectrometer , 1989, FEBS letters.
[22] F. Coe,et al. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. , 1989, The American journal of physiology.
[23] A. Craig,et al. Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. , 1989, The Journal of biological chemistry.
[24] W. Butler,et al. The nature and significance of osteopontin. , 1989, Connective tissue research.
[25] F. Coe,et al. Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. , 1988, The American journal of physiology.
[26] G. Mandel,et al. Specificity in calcium oxalate adherence to papillary epithelial cells in cultures. , 1988, The American journal of physiology.
[27] M. Ploug,et al. Carbohydrate as covalent crosslink in human inter‐α‐trypsin inhibitor: A novel plasma protein structure , 1988, FEBS letters.
[28] Y. Nakagawa,et al. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. , 1987, The Journal of clinical investigation.
[29] S. Ljunghall,et al. Crystal inhibition: the effects of polyanions on calcium oxalate crystal growth. , 1986, Clinica chimica acta; international journal of clinical chemistry.
[30] F. Coe,et al. Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. , 1985, The Journal of clinical investigation.
[31] S. Weiner,et al. Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[32] E. Kaiser,et al. Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. , 1983, The Journal of biological chemistry.
[33] A. Wheeler,et al. Control of calcium carbonate nucleation and crystal growth by soluble matrx of oyster shell. , 1981, Science.
[34] R. Ryall,et al. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[35] E. Kaiser,et al. Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. , 1981, The Journal of biological chemistry.
[36] H. Fleisch. Inhibitors and promoters of stone formation. , 1978, Kidney international.
[37] B. Finlayson,et al. The expectation of free and fixed particles in urinary stone disease. , 1978, Investigative urology.
[38] C. Pak,et al. Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. , 1976, Metabolism: clinical and experimental.
[39] M. Peacock,et al. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. , 1972, Clinical science.
[40] E. G. McQueen,et al. Factors determining the aggregation of urinary mucoprotein , 1966, Journal of clinical pathology.